Acarix AB's total inventories for the quarter that ended in Mar. 2026 was kr6.25 Mil. Acarix AB's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was kr6.36 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Acarix AB's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was kr0.02.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Acarix AB's Days Inventory for the
three
months ended in Mar. 2026 was 1,272.00.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Acarix AB's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.07.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Acarix AB's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 2.62.
Acarix AB (OSTO:ACARIX) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Acarix AB's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Acarix AB's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Acarix AB Total Inventories Related Terms
Acarix AB Total Inventories Historical Data
* Premium members only.
The historical data trend for Acarix AB's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Acarix AB (OSTO:ACARIX) has a Total Inventories of kr6.25 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Acarix AB and its competitors.
Is Acarix AB's Total Inventories too high?
Acarix AB's current Total Inventories is kr6.25 Mil. Overall, Acarix AB has a GF Score™ of 44/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Total Inventories compare to ABT and SYK?
Acarix AB's Total Inventories of kr6.25 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Acarix AB and its competitors. Acarix AB's current Total Inventories is kr6.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (OSTO:ACARIX) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.23, compared to a current price of kr0.26 — trading 14.6% above its estimated fair value. The current Total Inventories is kr6.25 Mil. Acarix AB's overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Acarix AB (OSTO:ACARIX), the current Total Inventories is kr6.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (OSTO:ACARIX) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued.
The current stock price of kr0.26 is trading 14.6% above its estimated GF Value™ of kr0.23.
GuruFocus considers Acarix AB to be Modestly Overvalued.
Key valuation signals for OSTO:ACARIX:
Total Inventories: kr6.25 Mil
GF Value™: kr0.23 vs. price of kr0.26 (14.6% above fair value)
No single metric tells the full story. See the OSTO:ACARIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
44GF Score
Get the complete analysis for OSTO:ACARIX
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ACARIX has been successfully added to your 
